Intermittent Claudication Market Report 2026

The intermittent claudication market size has grown strongly in recent years. It will grow from $13.51 billion in 2025 to $14.31 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising prevalence of peripheral artery disease, increasing aging population, high incidence of smoking-related vascular disorders, growth in cardiovascular disease burden, expanded availability of vascular intervention procedures.

The intermittent claudication market size is expected to see strong growth in the next few years. It will grow to $17.98 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing awareness of peripheral artery disease symptoms, growing demand for minimally invasive vascular treatments, advancements in pharmacological therapies, rising adoption of home-based disease management, improved screening and diagnostic programs. Major trends in the forecast period include increasing focus on early diagnosis of peripheral artery disease, rising adoption of combination drug therapies, growing preference for minimally invasive revascularization procedures, expansion of supervised exercise therapy programs, improved patient awareness and disease management.

The rising prevalence of peripheral artery disease (PAD) is expected to drive the growth of the intermittent claudication market in the coming years. Peripheral artery disease is a circulatory disorder characterized by narrowed arteries that restrict blood flow to the limbs, resulting in pain, numbness, and related complications. The growing incidence of peripheral artery disease is linked to factors such as an aging population, diabetes, smoking, hypertension, obesity, and inactive lifestyles. Peripheral artery disease (PAD) leads to intermittent claudication by limiting blood supply to the leg muscles during physical activity, causing pain and cramping due to insufficient oxygen delivery. For example, in June 2023, according to the American Heart Association Journals, a U.S.-based peer-reviewed open-access scientific journal, peripheral artery disease (PAD) affects approximately 7-12 million people in the U.S. and around 200 million worldwide. Hence, the increasing burden of peripheral artery disease (PAD) is contributing to the expansion of the intermittent claudication market.

Leading companies in the intermittent claudication market are emphasizing the integration of minimally invasive endovascular advancements, such as percutaneous bypass systems, to improve treatment effectiveness, procedural outcomes, and overall patient recovery. Percutaneous bypass systems are sophisticated vascular solutions that establish an endovascular bypass route using specialized stent grafts and catheters, allowing functions such as reestablishing blood flow across extensive arterial obstructions, minimizing the need for open surgical bypass, and enabling quicker patient recovery. For example, in June 2023, Endologix LLC, a U.S.-based medical device company focused on vascular disease therapies, obtained FDA approval for its DETOUR System, a minimally invasive percutaneous bypass solution intended to treat long and complex superficial femoropopliteal lesions in patients with peripheral artery disease (PAD). The system incorporates the TORUS stent graft platform, an innovative endovascular bypass approach, and the ability to manage long-segment occlusions, supporting effective treatment of difficult femoropopliteal blockages. The DETOUR System improves blood flow restoration, lowers procedural morbidity, and broadens therapeutic options for patients with symptomatic PAD and intermittent claudication.

In April 2023, Abbott Laboratories, a U.S.-based healthcare company, acquired Cardiovascular Systems Inc. for $890 million. Through this acquisition, Abbott seeks to expand its vascular device portfolio by integrating Cardiovascular Systems Inc.’s advanced technologies for the treatment of peripheral and coronary artery disease. This transaction reinforces Abbott’s presence in the cardiovascular sector and improves patient outcomes through enhanced minimally invasive treatment solutions. Cardiovascular Systems Inc. is a U.S.-based medical device company that focuses on delivering innovative therapies for peripheral artery disease (PAD), including intermittent claudication.

Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Alkem Laboratories, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma.

North America was the largest region in the intermittent claudication market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intermittent claudication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the intermittent claudication market by increasing costs of imported medical devices, vascular intervention tools, and pharmaceutical ingredients used in treatment. These effects are most evident in revascularization and medication therapy segments, particularly across asia-pacific and europe where reliance on cross-border sourcing is significant. Higher tariffs have increased treatment and procedural costs for hospitals and clinics. However, tariffs are also encouraging domestic manufacturing of vascular devices, local drug production, and supply chain diversification, supporting long-term market resilience.

The intermittent claudication market research report is one of a series of new reports that provides intermittent claudication market statistics, including intermittent claudication industry global market size, regional shares, competitors with a intermittent claudication market share, detailed intermittent claudication market segments, market trends and opportunities, and any further data you may need to thrive in the intermittent claudication industry. This intermittent claudication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intermittent claudication is a condition marked by muscle pain, cramping, or discomfort in the legs that arises during physical exertion, such as walking, and subsides with rest. It is most commonly associated with peripheral artery disease (PAD), a condition caused by the narrowing or blockage of arteries that limits blood flow to the muscles. The discomfort typically occurs due to an inadequate supply of oxygen (ischemia) to the affected muscle tissues.

The primary approaches to managing intermittent claudication include medication-based therapies and revascularization procedures. Medication therapies focus on relieving symptoms, improving blood circulation, reducing pain, and preventing complications related to impaired blood flow. These treatments are delivered through multiple routes, including oral, parenteral, and other methods, and are provided across various care settings such as hospitals, clinics, home healthcare, and others. The medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The intermittent claudication market includes revenues earned by entities by providing services such as non-invasive tests, angioplasty, stent placement, supervised exercise therapy, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The intermittent claudication market also consists of sales of antiplatelet agents, statins, vasodilators, and special socks or stockings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.